Developing Active Anti-angiogenic Immunotherapies for Cancer Patients
VAXIMM is a privately held, Swiss-based vaccine company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Our initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VXM01 has shown impressive anti-tumor activity in various animal studies and is currently being evaluated in clinical trials. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA. Besides VXM01, VAXIMM has a pipeline of complementary candidate vaccines.